ESR1 and breast carcinoma: We also included CTNNB1 in the analysis since CTNNB1-related signatures were enriched in ER+/HER2- breast cancer patients resistant to taxane-based therapy and high expression of CTNNB1 was associated with decreased survival in ER+/HER2- breast cancer patients (Figures 3A, B, D).